p53-mediated regulation of cell cycle progression: Pronounced impact of cellular microenvironment

Journal of Cellular Physiology

Volumn 219, Issue 2, 2009, Pages 459-469

  Schmid, Gerald ^a,b   Kramer, Matthias P ^a   Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; VALINE; PROTEIN P21;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CLONE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; EMBRYO; GENE OVEREXPRESSION; GENETIC TRANSFECTION; MICROENVIRONMENT; NONHUMAN; ONCOGENE C H RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; TEMPERATURE SENSITIVITY; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; CELL CYCLE; CELL LINE; CYTOLOGY; ENVIRONMENT; FEMALE; GENETICS; GESTATIONAL AGE; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PREGNANCY; TEMPERATURE;

RATTUS;

ANIMALS; CELL CYCLE; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELLS, CULTURED; EMBRYO, MAMMALIAN; ENVIRONMENT; FEMALE; GESTATIONAL AGE; HUMANS; MICE; PREGNANCY; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; TEMPERATURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62149149943     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21705     Document Type: Article

References (60)

1. Banerjee K, Das SK, Mukherjee P. 2003. Immunocytochemical detection of p21ras, Raf-1, ERK1/MAP kinase and PKC isoforms in a 20-methylcholanthrene- induced transformed murine embryonal fibroblast cells in culture. Neoplasma 50:131-138.
2. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107-120.
3. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. 2003. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846-851.
4. Bernstein C, Bernstein H, Payne CM, Garewal H. 2002. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 511:145-178.
5. Blagosklonny MV. 2002. P53: An ubiquitous target of anticancer drugs. Int J Cancer 98:161-166.
6. Cohen JB, Broz SD, Levinson AD. 1989. Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell 58:461-472.
7. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, Oren M, Hainaut P. 2002. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722-6728.
8. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319.
9. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G. 1998. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188:1763-1768.
10. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, Levrero M, Knight RA. 1999. Additional complexity in p73: Induction bymitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 6:389-390.
11. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
12. Ehrhardt A, Ehrhardt GR, Guo X, Schrader JW. 2002. Ras and relatives - Job sharing and networking keep an old family together. Exp Hematol 30:1089-1106.
13. Eliyahu D, Michalovitz D, Oren M. 1985. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158-160.
14. Evans SC, Lozano G. 1997. The Li-Fraumeni syndrome: An inherited susceptibility to cancer. Mol Med Today 3:390-395.
15. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A. 2007. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 67:2187-2196.
16. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM, Yu W, Maitra A. 2008. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57:1420-1430.
17. French JE, Lacks GD, Trempus C, Dunnick JK, Foley J, Mahler J, Tice RR, Tennant RW. 2001. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis 22:99-106.
18. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. 1997. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 16:1381-1390.
19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
20. Guil S, de La Iglesia N, Fernandez-Larrea J, Cifuentes D, Ferrer JC, Guinovart JJ, Bach-Elias M. 2003a. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Res 63:5178-5187.
21. Guil S, Gattoni R, Carrascal M, Abian J, Stevenin J, Bach-Elias M. 2003b. Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol 23:2927-2941.
22. Halevy O, Michalovitz D, Oren M. 1990. Different tumor-derived p53 mutants exhibit distinct biological activities. Science (New York, NY) 250:113-116.
23. Harris CC. 1996. p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 104:435-439.
24. Hisada M, Garber JE, Fung CY, Fraumeni JF, Jr., Li FP. 1998. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606-611.
25. Huang MY, Cohen JB. 1997. The alternative H-ras protein p19 displays properties of a negative regulator of p21Ras. Oncol Res 9:611-621.
26. Ide F, Kitada M, Sakashita H, Kusama K, Tanaka K, Ishikawa T. 2003. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. Am J Pathol 163:1729-1733. (Pubitemid 37310003)
27. Inga A, Storici F, Darden TA, Resnick MA. 2002. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22:8612-8625.
28. Janicke RU, Sohn D, Schulze-Osthoff K. 2008. The dark side of a tumor suppressor: Antiapoptotic p53. Cell Death Differ 15:959-976.
29. Ji Z, Mei FC, Xie J, Cheng X. 2007. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 282:14048-14055.
30. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
31. Kalderon D. 2000. Transducing the hedgehog signal. Cell 103:371-374.
32. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
33. Kolch W. 2000. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289-305.
34. Kovar H, Jug G, Printz D, Bartl S, Schmid G, Wesierska-Gadek J. 2000. Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8. Oncogene 19:4096-4107.
35. Laptenko O, Prives C. 2006. Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ 13:951-961.
36. Lau J, Kawahira H, Hebrok M. 2006. Hedgehog signaling in pancreas development and disease. Cell Mol Life Sci 63:642-652.
37. Li FP, Fraumeni JF, Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A. familial syndrome? Ann Intern Med 71:747-752.
38. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
39. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. 1999. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 450:197-204.
40. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M. 2006. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20:3161-3173.
41. Prives C, Hall PA. 1999. The p53 pathway. J Pathol 187:112-126.
42. Remboutsika E, Lutz Y, Gansmuller A, Vonesch JL, Losson R, Chambon P. 1999. The putative nuclear receptor mediator TIF1alpha is tightly associated with euchromatin. J Cell Sci 112:1671-1683.
43. Schmid G, Kramer MP, Maurer M, Wandl S, Wesierska-Gadek J. 2007. Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence. J Cell Biochem 101:1355-1369.
44. Taurin S, Seyrantepe V, Orlov SN, Tremblay TL, Thibault P, Bennett MR, Hamet P, Pshezhetsky AV. 2002. Proteome analysis and functional expression identify mortalin as an antiapoptotic gene induced by elevation of [Na+]i/[K+]i ratio in cultured vascular smooth muscle cells. Circ Res 91:915-922.
45. Taylor WR, Egan SE, Mowat M, Greenberg AH, Wright JA. 1992. Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 7:1383-1390.
46. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856.
47. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev 6:909-923.
48. van der Weyden L, Adams DJ. 2007. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 1776:58-85.
49. Viktorsson K, De Petris L, Lewensohn R. 2005. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331:868-880.
50. Vindelov LL, Christensen IJ, Nissen NI. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327.
51. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, Kaul SC. 2006. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 118:2973-2980.
52. Wesierska-Gadek J, Schmid G. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80:85-103.
53. Wesierska-Gadek J, Schmid G. 2001. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Cell Mol Biol Lett 6:117-140.
54. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. 1995. Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Acta Biochim Pol 42:197-200.
55. Wesierska-Gadek J, Bugajska-Schretter A, Cerni C. 1996. ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified. J Cell Biochem 62:90-101.
56. Witz IP, Levy-Nissenbaum O. 2006. The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1-10.
57. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.
58. Yin Y, Stephen CW, Luciani MG, Fahraeus R. 2002. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4:462-467. (Pubitemid 34746166)
59. Zhang Z, Yao R, Li J, Wang Y, Boone CW, Lubet RA, You M. 2005. Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53. Mol Cancer Res 3:563-574.
60. Zhang Z, Wang Y, Yao R, Li J, Lubet RA, You M. 2006. p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer. Mol Cancer Res 4:401-410. (Pubitemid 44035159)